Advanced

End-stage renal disease associated with prophylactic lithium treatment.

Aiff, Harald; Attman, Per-Ola; Aurell, Mattias; Bendz, Hans LU ; Schön, Staffan and Svedlund, Jan (2014) In European Neuropsychopharmacology 24(4). p.540-544
Abstract
The primary aim of this study was to estimate the prevalence of lithium associated end-stage renal disease (ESRD) and to compare the relative risk of ESRD in lithium users versus non-lithium users. Second, the role of lithium in the pathogenesis of ESRD was evaluated. We used the Swedish Renal Registry to search for lithium-treated patients with ESRD among 2644 patients with chronic renal replacement therapy (RRT)-either dialysis or transplantation, within two defined geographical areas in Sweden with 2.8 million inhabitants. The prevalence date was December 31, 2010. We found 30 ESRD patients with a history of lithium treatment. ESRD with RRT was significantly more prevalent among lithium users than among non-lithium users (p<0.001).... (More)
The primary aim of this study was to estimate the prevalence of lithium associated end-stage renal disease (ESRD) and to compare the relative risk of ESRD in lithium users versus non-lithium users. Second, the role of lithium in the pathogenesis of ESRD was evaluated. We used the Swedish Renal Registry to search for lithium-treated patients with ESRD among 2644 patients with chronic renal replacement therapy (RRT)-either dialysis or transplantation, within two defined geographical areas in Sweden with 2.8 million inhabitants. The prevalence date was December 31, 2010. We found 30 ESRD patients with a history of lithium treatment. ESRD with RRT was significantly more prevalent among lithium users than among non-lithium users (p<0.001). The prevalence of ESRD with RRT in the lithium user population was 15.0‰ (95% CI 9.7-20.3), and close to two percent of the RRT population were lithium users. The relative risk of ESRD with RRT in the lithium user population compared with the general population was 7.8 (95% CI 5.4-11.1). Out of those 30 patients, lithium use was classified, based on chart reviews, as being the sole (n=14) or main (n=10) cause of ESRD in 24 cases. Their mean age at the start of RRT was 66 years (46-82), their mean time on lithium 27 years (12-39), and 22 of them had been on lithium for 15 years or more. We conclude that lithium-associated ESRD is an uncommon but not rare complication of lithium treatment. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European Neuropsychopharmacology
volume
24
issue
4
pages
540 - 544
publisher
Elsevier
external identifiers
  • pmid:24503277
  • wos:000334136000007
  • scopus:84895899926
ISSN
1873-7862
DOI
10.1016/j.euroneuro.2014.01.002
language
English
LU publication?
yes
id
75ca9992-5cb5-4782-8e3f-21c73fa4edf9 (old id 4335444)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24503277?dopt=Abstract
date added to LUP
2014-03-06 19:45:19
date last changed
2017-11-12 03:13:33
@article{75ca9992-5cb5-4782-8e3f-21c73fa4edf9,
  abstract     = {The primary aim of this study was to estimate the prevalence of lithium associated end-stage renal disease (ESRD) and to compare the relative risk of ESRD in lithium users versus non-lithium users. Second, the role of lithium in the pathogenesis of ESRD was evaluated. We used the Swedish Renal Registry to search for lithium-treated patients with ESRD among 2644 patients with chronic renal replacement therapy (RRT)-either dialysis or transplantation, within two defined geographical areas in Sweden with 2.8 million inhabitants. The prevalence date was December 31, 2010. We found 30 ESRD patients with a history of lithium treatment. ESRD with RRT was significantly more prevalent among lithium users than among non-lithium users (p&lt;0.001). The prevalence of ESRD with RRT in the lithium user population was 15.0‰ (95% CI 9.7-20.3), and close to two percent of the RRT population were lithium users. The relative risk of ESRD with RRT in the lithium user population compared with the general population was 7.8 (95% CI 5.4-11.1). Out of those 30 patients, lithium use was classified, based on chart reviews, as being the sole (n=14) or main (n=10) cause of ESRD in 24 cases. Their mean age at the start of RRT was 66 years (46-82), their mean time on lithium 27 years (12-39), and 22 of them had been on lithium for 15 years or more. We conclude that lithium-associated ESRD is an uncommon but not rare complication of lithium treatment.},
  author       = {Aiff, Harald and Attman, Per-Ola and Aurell, Mattias and Bendz, Hans and Schön, Staffan and Svedlund, Jan},
  issn         = {1873-7862},
  language     = {eng},
  number       = {4},
  pages        = {540--544},
  publisher    = {Elsevier},
  series       = {European Neuropsychopharmacology},
  title        = {End-stage renal disease associated with prophylactic lithium treatment.},
  url          = {http://dx.doi.org/10.1016/j.euroneuro.2014.01.002},
  volume       = {24},
  year         = {2014},
}